Vital Signs The Analyst's Perspective - August 2015 Issue

USD 450.00

* Required Fields

USD 450.00


Be the first to review this product

This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

Table of Contents

Vital Signs The Analyst's Perspective - August 2015 IssueVital Signs - August 2015 IssueAugust Issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.